Why the study?
Metabolic reprogramming plays a critical role in pulmonary arterial hypertension pathogenesis, and understanding mitochondrial metabolic mechanisms could provide viable therapeutic approaches.
Understanding mitochondrial metabolic mechanisms in PAH could provide viable therapeutic approaches for patients.
Answers are grounded in this paper and cite their sources.
Mitochondrial pathway modulation should not yet change PAH practice; leaves open whether it extends current vasodilator strategies.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary arterial pressure due to increased pulmonary vascular resistance, secondary to sustained pulmonary vasoconstriction and excessive obliterative pulmonary vascular remodeling. Work over the last decade has led to the identification of a critical role for metabolic reprogramming in the PAH pathogenesis. It is becoming clear that in addition to its role in ATP generation, the mitochondrion is an important organelle that regulates complex and integrative metabolic- and signal transduction pathways. This review focuses on mitochondrial metabolism alterations that occur in deranged pulmonary vessels and the right ventricle, including abnormalities in glycolysis and glucose oxidation, fatty acid oxidation, glutaminolysis, redox homeostasis, as well as iron and calcium metabolism. Further understanding of these mitochondrial metabolic mechanisms could provide viable therapeutic approaches for PAH patients.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: